ESC 365 - Efficacy and safety of sacubitril/valsartan (LCZ696) in reducing adverse cardiovascular events and controlling hypertension among asians: a meta-analysis of randomised controlled trials

HFA Premium Access

Efficacy and safety of sacubitril/valsartan (LCZ696) in reducing adverse cardiovascular events and controlling hypertension among asians: a meta-analysis of randomised controlled trials

Session: Heart Failure ePosters - focus on Pharmacology and other topics

Topic: Cardiovascular Pharmacotherapy

Speaker: Doctor P. Vera Cruz (Quezon, PH)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Doctor Patrick Vera Cruz

St. Luke's Medical Center, Quezon (Philippines)

0 follower

30 more presentations in this session

Role of empagliflozin in diabetic patient with acute myocardial infarction who undergone percutaneous coronary intervention

Recovery of left ventricular ejection fraction in patients treated with sacubitril/valsartan

Speaker: Doctor J. Mesquita Guimaraes (Coimbra, PT)

Levosimendan bridge to therapy optimization

Speaker: Doctor C. Moliner-Abos (Barcelona, ES)

ORal anti-coagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the ORIGAMI pilot investigation

Speaker: Doctor D. D'Amario (Novara, IT)

Beta-blockers and ivabradine titration in HF patients with LV only fusion pacing CRT

Speaker: Doctor C. Vacarescu (Timisoara, RO)

Access the full session

Heart Failure ePosters - focus on Pharmacology and other topics

Speakers: Doctor P. Vera Cruz, Doctor J. Mesquita Guimaraes, Doctor C. Moliner-Abos, Doctor D. D'Amario, Doctor C. Vacarescu

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources